Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib
Public ClinicalTrials.gov record NCT00101660. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Study to Determine the Activity of BMS-354825 in Subjects With Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Disease That is Resistant to High Dose Imatinib Mesylate (Gleevec) or Who Are Intolerant of Imatinib
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is assess the effects of the investigational drug dasatinib on participants who are in chronic phase Philadelphia chromosome chronic myeloid leukemia and who are either resistant to or intolerant of imatinib. Other purposes of the study are to identify any side effects the drug may produce and to study the level of dasatanib in the blood and assess the efficacy of dasatanib in the treatment of leukemia.
Study identification
- NCT ID
- NCT00101660
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 387 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 2005 (Type not available)
- Primary completion
- Sep 2006 (Actual)
- Completion
- Apr 2008 (Actual)
- Last update posted
- Mar 2, 2012
2005 – 2008
United States locations
- U.S. sites
- 32
- U.S. states
- 21
- U.S. cities
- 32
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution | Anaheim | California | — | — |
| Local Institution | Loma Linda | California | — | — |
| Local Institution | Los Angeles | California | — | — |
| Local Institution | Stanford | California | — | — |
| Local Institution | Vallejo | California | — | — |
| Local Institution | Hartford | Connecticut | — | — |
| Local Institution | Washington D.C. | District of Columbia | — | — |
| Local Institution | Jacksonville | Florida | — | — |
| Local Institution | Tampa | Florida | — | — |
| Local Institution | Atlanta | Georgia | — | — |
| Local Institution | Chicago | Illinois | — | — |
| Local Institution | Indianapolis | Indiana | — | — |
| Local Institution | Kansas City | Kansas | — | — |
| Local Institution | Baltimore | Maryland | — | — |
| Local Institution | Boston | Massachusetts | — | — |
| Local Institution | Detroit | Michigan | — | — |
| Local Institution | Kansas City | Missouri | — | — |
| Local Institution | St Louis | Missouri | — | — |
| Local Institution | Omaha | Nebraska | — | — |
| Local Institution | Hackensack | New Jersey | — | — |
| Local Institution | New Brunswick | New Jersey | — | — |
| Local Institution | New York | New York | — | — |
| Local Institution | Portland | Oregon | — | — |
| Local Institution | Philadelphia | Pennsylvania | — | — |
| Local Institution | Pittsburgh | Pennsylvania | — | — |
| Local Institution | Greenville | South Carolina | — | — |
| Local Institution | Nashville | Tennessee | — | — |
| Local Institution | Dallas | Texas | — | — |
| Local Institution | Houston | Texas | — | — |
| Local Institution | San Antonio | Texas | — | — |
| Local Institution | Tyler | Texas | — | — |
| Local Institution | Spokane | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 53 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00101660, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 2, 2012 · Synced Nov 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00101660 live on ClinicalTrials.gov.